9 May 2023
Dr. Marzia Del Re from the University of Pisa discusses her research on liquid biopsy for predictive biomarkers of resistance or response to targeted therapies in patients with solid tumors. She uses digital PCR and next-generation sequencing for her research and suggests using digital PCR for molecular identification and diagnosis of point mutations or small insertions and deletions and using next-generation sequencing for large gene rearrangements or fusions. Del Re expects an increase in the use of digital PCR for patient monitoring during treatment and believes that assessing minimal residual disease and monitoring tumor dynamics during treatment will be the next step for liquid biopsy in the clinical setting.
This video was filmed at AACR 2023.